Cardiac Tissue Engineering and Regeneration Using Cell-based Therapy

Overview

Journal Stem Cells Cloning

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 May 23

PMID 25999743

Citations 26

Authors

Mohammad T Alrefai

Divya Murali

Arghya Paul

Khalid M Ridwan

John M Connell

Dominique Shum-Tim

Affiliations

Soon will be listed here.

Abstract

Stem cell therapy and tissue engineering represent a forefront of current research in the treatment of heart disease. With these technologies, advancements are being made into therapies for acute ischemic myocardial injury and chronic, otherwise nonreversible, myocardial failure. The current clinical management of cardiac ischemia deals with reestablishing perfusion to the heart but not dealing with the irreversible damage caused by the occlusion or stenosis of the supplying vessels. The applications of these new technologies are not yet fully established as part of the management of cardiac diseases but will become so in the near future. The discussion presented here reviews some of the pioneering works at this new frontier. Key results of allogeneic and autologous stem cell trials are presented, including the use of embryonic, bone marrow-derived, adipose-derived, and resident cardiac stem cells.

Citing Articles

Influence of Super-Low-Intensity Microwave Radiation on Mesenchymal Stem Cells.

Artamonov M, Pyatakovich F, Minenko I Int J Mol Sci. 2025; 26(4).

PMID: 40004170 PMC: 11855362. DOI: 10.3390/ijms26041705.

Development of Novel 3D Spheroids for Discrete Subaortic Stenosis.

Brimmer S, Ji P, Birla R, Heinle J, Grande-Allen J, Keswani S Cardiovasc Eng Technol. 2024; 15(6):704-715.

PMID: 39495395 DOI: 10.1007/s13239-024-00746-x.

In silico Mechanics of Stem Cells Intramyocardially Transplanted with a Biomaterial Injectate for Treatment of Myocardial Infarction.

Motchon Y, Sack K, Sirry M, Nchejane N, Abdalrahman T, Nagawa J Cardiovasc Eng Technol. 2024; 15(5):594-605.

PMID: 38782879 PMC: 11582092. DOI: 10.1007/s13239-024-00734-1.

Cell Therapy in the Treatment of Coronary Heart Disease.

Chepeleva E Int J Mol Sci. 2023; 24(23).

PMID: 38069167 PMC: 10706847. DOI: 10.3390/ijms242316844.

Latest Advances in 3D Bioprinting of Cardiac Tissues.

Jafari A, Ajji Z, Mousavi A, Naghieh S, Bencherif S, Savoji H Adv Mater Technol. 2023; 7(11).

PMID: 38044954 PMC: 10691862. DOI: 10.1002/admt.202101636.

References

Gluckman E . Ten years of cord blood transplantation: from bench to bedside. Br J Haematol. 2009; 147(2):192-9. DOI: 10.1111/j.1365-2141.2009.07780.x. View

Ellison G, Torella D, Dellegrottaglie S, Perez-Martinez C, de Prado A, Vicinanza C . Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol. 2011; 58(9):977-86. DOI: 10.1016/j.jacc.2011.05.013. View

Iop L, Bonetti A, Naso F, Rizzo S, Cagnin S, Bianco R . Decellularized allogeneic heart valves demonstrate self-regeneration potential after a long-term preclinical evaluation. PLoS One. 2014; 9(6):e99593. PMC: 4062459. DOI: 10.1371/journal.pone.0099593. View

Ota T, Gilbert T, Badylak S, Schwartzman D, Zenati M . Electromechanical characterization of a tissue-engineered myocardial patch derived from extracellular matrix. J Thorac Cardiovasc Surg. 2007; 133(4):979-85. DOI: 10.1016/j.jtcvs.2006.11.035. View

Losordo D, Schatz R, White C, Udelson J, Veereshwarayya V, Durgin M . Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007; 115(25):3165-72. DOI: 10.1161/CIRCULATIONAHA.106.687376. View

Traverse J, Henry T, Vaughan D, Ellis S, Pepine C, Willerson J . LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20. PMC: 2929864. View

Burridge P, Keller G, Gold J, Wu J . Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012; 10(1):16-28. PMC: 3255078. DOI: 10.1016/j.stem.2011.12.013. View

Kattman S, Witty A, Gagliardi M, Dubois N, Niapour M, Hotta A . Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 2011; 8(2):228-40. DOI: 10.1016/j.stem.2010.12.008. View

Strauer B, Yousef M, Schannwell C . The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010; 12(7):721-9. DOI: 10.1093/eurjhf/hfq095. View

10.

Li R, Jia Z, Weisel R, Mickle D, Choi A, Yau T . Survival and function of bioengineered cardiac grafts. Circulation. 1999; 100(19 Suppl):II63-9. DOI: 10.1161/01.cir.100.suppl_2.ii-63. View

11.

Paul A, Hasan A, Rodes L, Sangaralingam M, Prakash S . Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: principles, prospects and challenges. Adv Drug Deliv Rev. 2014; 71:115-30. DOI: 10.1016/j.addr.2014.01.004. View

12.

Meyer G, Wollert K, Lotz J, Steffens J, Lippolt P, Fichtner S . Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006; 113(10):1287-94. DOI: 10.1161/CIRCULATIONAHA.105.575118. View

13.

Sekine H, Shimizu T, Sakaguchi K, Dobashi I, Wada M, Yamato M . In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels. Nat Commun. 2013; 4:1399. PMC: 3660653. DOI: 10.1038/ncomms2406. View

14.

Fernandes S, Naumova A, Zhu W, Laflamme M, Gold J, Murry C . Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J Mol Cell Cardiol. 2010; 49(6):941-9. PMC: 2992844. DOI: 10.1016/j.yjmcc.2010.09.008. View

15.

Badylak S . Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transpl Immunol. 2004; 12(3-4):367-77. DOI: 10.1016/j.trim.2003.12.016. View

16.

Povsic T, Junge C, Nada A, Schatz R, Harrington R, Davidson C . A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013; 165(6):854-861.e2. DOI: 10.1016/j.ahj.2013.03.003. View

17.

Masuda S, Shimizu T, Yamato M, Okano T . Cell sheet engineering for heart tissue repair. Adv Drug Deliv Rev. 2007; 60(2):277-85. DOI: 10.1016/j.addr.2007.08.031. View

18.

Bursac N, Papadaki M, Cohen R, Schoen F, Eisenberg S, Carrier R . Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies. Am J Physiol. 1999; 277(2):H433-44. DOI: 10.1152/ajpheart.1999.277.2.H433. View

19.

Ranganath S, Levy O, Inamdar M, Karp J . Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10(3):244-58. PMC: 3294273. DOI: 10.1016/j.stem.2012.02.005. View

20.

Akhyari P, Aubin H, Gwanmesia P, Barth M, Hoffmann S, Huelsmann J . The quest for an optimized protocol for whole-heart decellularization: a comparison of three popular and a novel decellularization technique and their diverse effects on crucial extracellular matrix qualities. Tissue Eng Part C Methods. 2011; 17(9):915-26. DOI: 10.1089/ten.TEC.2011.0210. View